A new analysis by health policy researchers at the University of Massachusetts Amherst who studied the effectiveness of the 1983 Orphan Drug Act (ODA) finds that current incentives "are not sufficiently stimulating orphan ...
Feb 15, 2017
0
0
From reading and hearing news accounts, the general public has a vague impression that some things are amiss with the pharmaceutical industry—one word: Epipens. But few might consider it an industry in a state of collapse.
Jan 12, 2017
0
49
Incentives intended to stimulate the development of more treatments for rare diseases are being exploited to boost the profits of pharmaceutical companies, new research led by Bangor University shows.
Oct 21, 2016
3
94
Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs.
Sep 9, 2016
0
4
Health experts at Johns Hopkins Medicine are calling on lawmakers and regulators to close loopholes in the Orphan Drug Act they claim give drug companies millions of dollars in unintended and misplaced subsidies and tax breaks ...
Nov 19, 2015
0
7
Faced with expiring patents and growing competition from generics, pharmaceutical companies increasingly view orphan drugs as a key pathway to growth.
Aug 6, 2015
0
4
In developing an orphan drug policy, Canada must ensure that all orphan drugs for rare diseases—both old and future drugs—should be priced fairly so that Canadians may access life-saving therapy, argue authors of an analysis ...
Feb 23, 2015
0
3
The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years.
Jan 2, 2015
0
12
(Medical Xpress)—Though pharmaceutical companies that are developing "orphan drugs" do so mainly for the business potential, the companies also consider the effort as part of their corporate social responsibility, management ...
Apr 1, 2013
0
0
How can insurers justify spending hundreds of thousands of dollars per patient per year on "orphan drugs" – extremely expensive medications for rare conditions that are mostly chronic and life-threatening -- when this ...
Feb 7, 2012
0
0
